Sector revisions Perspective Therapeutics, Inc.

Stocks

Market Closed - NYSE Other stock markets 04:00:00 2026-08-07 pm EDT			5-day change	1st Jan Change
3.000 ^USD	+1.01%		+3.09%	+9.09%

Jul. 28	Perspective Therapeutics' Neuroendocrine Tumor Therapy Receives EU Orphan Drug Designation	MT
Jul. 17	Perspective Therapeutics Data On 212Pb VMT-a-NET Accepted For Oral Presentation At ESMO Congress 2026	CI

Sector:

Location:

X axis:

Main competitors

Add to a list 0 selected To use this feature you must be a member Log in Sign up	1y. EPS revision	Nbr of analysts
PERSPECTIVE THERAPEUTICS, INC.		14
LONZA GROUP AG		23
REVOLUTION MEDICINES, INC.		21
BEONE MEDICINES AG		25
IQVIA HOLDINGS INC.		18
CELLTRION, INC.		24
ASCENDIS PHARMA A/S	-	18
MEDPACE HOLDINGS, INC.		12
EUROFINS SCIENTIFIC SE		14
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.		14
ICON PUBLIC LIMITED COMPANY		16
ABIVAX		6
BIO-TECHNE CORPORATION		11
PHARMARON BEIJING CO., LTD.		11
APOGEE THERAPEUTICS, INC.		12
PRAXIS PRECISION MEDICINES, INC.		18
IONIS PHARMACEUTICALS, INC.		21
TEMPUS AI, INC.		14
PROTAGONIST THERAPEUTICS, INC.		13
KYMERA THERAPEUTICS, INC.		22
Average		16
Weighted average by Cap.		19